title: Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose.
abstract: There is a small proportion of cells within a tumour with self-renewing properties, which is resistant to conventional therapy, and is responsible for tumour initiation, maintenance and metastasis. These cells are known as cancer stem cells (CSCs) or tumour-initiating cells (TICs) [1]. Recent publications identify several antibiotics, such as salinomycin or doxycycline, as selective CSCs inhibitors [2-4]. However, the mechanisms of action of these antibiotics on CSCs are not fully understood.
authors.affiliation: The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK ; The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, Manchester, UK.
authors.forename: Maria
authors.initials: M
authors.lastname: Peiris-Pagès
authors.affiliation: The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK ; The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, Manchester, UK.
authors.forename: Federica
authors.initials: F
authors.lastname: Sotgia
authors.affiliation: The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK ; The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, Manchester, UK.
authors.forename: Michael P
authors.initials: MP
authors.lastname: Lisanti
keywords: DNA damage response; DNA-PK; antibiotics for cancer therapy; cancer metabolism; cancer stem cells; doxycycline; drug repurposing; mitochondria